Exploration of peptides bound to MHC class I molecules in melanoma

Antonia L. Pritchard, Marcus L. Hastie, Michelle Neller, Jeffrey J. Gorman, Chris W. Schmidt, Nicholas K. Hayward

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


Advancements in high-resolution HPLC and mass spectrometry have reinvigorated the application of this technology to identify peptides eluted from immunopurified MHC class I molecules. Three melanoma cell lines were assessed using w6/32 isolation, peptide elution and HPLC purification; peptides were identified by mass spectrometry. A total of 13 829 peptides were identified; 83–87% of these were 8–11 mers. Only approximately 15% have been described before. Subcellular locations of the source proteins showed even sampling; mRNA expression and total protein length were predictive of the number of peptides detected from a single protein. HLA-type binding prediction for 10 078 9/10 mer peptides assigned 88–95% to a patient-specific HLA subtype, revealing a disparity in strength of predicted binding. HLA-B*27-specific isolation successfully identified some peptides not found using w6/32. Sixty peptides were selected for immune screening, based on source protein and predicted HLA binding; no new peptides recognized by antimelanoma T cells were discovered. Additionally, mass spectrometry was unable to identify several epitopes targeted ex vivo by one patient's T cells.
Original languageEnglish
Pages (from-to)281-294
Number of pages14
JournalPigment Cell and Melanoma Research
Issue number3
Early online date5 Mar 2015
Publication statusPublished - May 2015


  • melanoma
  • mass spectrometry
  • MHC class I
  • proteome
  • antigen
  • epitope
  • peptide


Dive into the research topics of 'Exploration of peptides bound to MHC class I molecules in melanoma'. Together they form a unique fingerprint.

Cite this